Product
Immune Globulin Subcutaneous
Aliases
Immune Globulin Infusion (Human), Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)
1 clinical trial
1 indication
Indication
Primary Immunodeficiency DiseasesClinical trial
A Phase 3, Open-label, Non-controlled, Multi-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Subjects With Primary Immunodeficiency Diseases (PID)Status: Completed, Estimated PCD: 2021-12-22